Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Global Antihistamines Market to 2026 - Key Players are Bayer, Almirall, Johnson & Johnson, AstraZeneca, Novartis, Pfizer, Sanofi, Boehringer Ingelheim, Merck & Co, Akorn & Teva

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

News provided by

Research and Markets

Sep 24, 2018, 09:00 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, Sept 24, 2018 /PRNewswire/ --

The "Global Antihistamines Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

The global antihistamines market will grow at a CAGR of 8.7% from 2018 to 2026.

Histamine is a key intermediary of instant hypersensitivity reactions acting locally and assisting vasodilation, smooth muscle contraction, high vascular permeability, inflammation, and edema. Antihistamines are representative of a class of drugs that inhibit the histamine type 1 (H1) receptors. H1 receptor is present on smooth muscle of bronchi, gastrointestinal tract, uterus, and large blood vessels.

The major application of antihistamines has been observed in treatment of symptoms such as allergic conditions including itching, runny nose, nasal stuffiness, urticaria, teary eyes, dizziness, cough, and nausea. A few common side effects observed due to antihistamines treatment are sedation, impaired motor function, dry mouth & throat, dizziness, blurred vision, constipation and urinary retention. However, since a few decades modern drug development technologies have helped to reduce aforementioned side effects of antihistamines.

The two classes of antihistamines comprise first generation and second generation antihistamines. The first generation antihistamines comprises of drugs such as alimemazine, clemastine, chlorphenamine, hydroxyzine, cyproheptadine, ketotifen, promethazine and others.

The drugs such as cetirizine, acrivastine, desloratadine, levocetirizine, fexofenadine, and loratadine. In 2017, second generation antihistamines segment was observed as the largest market as they are used as first line of action in diseases such as urticaria & common cold, and modern drug development technologies have assisted to enhance the activity of second generation antihistamines e.g.: Levocitirizine was developed from cetirizine to reduce dizziness caused by cetirizine. Thus, technological support is expected to develop the therapeutic effect of second generation antihistamines in the near future.

There are several applications of antihistamines such as allergic rhinitis, conjunctivitis, urticaria, atopic dermatitis, anaphylaxis and others (angioedema, pruritus, and others). Allergic rhinitis and urticaria together accounted more than 50% of the market share in year 2017 due to highest global prevalence of disease coupled with rising awareness and accessibility related to diagnosis and treatment of diseases. According to American Academy of Allergy Asthma & Immunology (AAAAI), globally allergic rhinitis affects around 10% to 30% of the population every year.

Thus, the prevalence of diseases determine the demand for antihistamines in the market.The global antihistamines market experiences huge competition due to the presence of several national and international market players. Since most of the drugs are generic and available over the counter which makes antihistamines market more competitive.

Key players in the market include Bayer AG, Almirall S.A., Johnson & Johnson, AstraZeneca plc, Novartis AG, Pfizer, Inc., Sanofi SA, Boehringer Ingelheim GmbH, Merck & Co., Inc., Akorn, Inc., Teva Pharmaceutical Industries Ltd., and others.


Key Market Movements

  • Globally, the antihistamines market will significantly grow at a CAGR of 8.7% for the period from 2018 to 2026
  • First generation and second generation antihistamines are further sub-segmented including drugs such as Chlorphenamine, Alimemazine, Clemastine, Hydroxyzine, Cyproheptadine, Ketotifen, Acrivastine, Promethazine, Cetirizine, Fexofenadine, Desloratadine, Loratadine, and Levocetirizine
  • Second generation antihistamines was identified as the largest market and expected to retain its dominance throughout the forecast period from 2018 to 2026
  • Asia Pacific was identified as most promising region in the near future during the forecast period 2018 to 2026

Key Topics Covered:

Chapter 1. Preface
1.1. Report Description
1.2. Research Scope
1.3. Research Methodology

Chapter 2. Executive Summary
2.1. Global Antihistamines Market Portraiture
2.2. Global Antihistamines Market, by Antihistamines Type, 2017 (US$ Mn)
2.3. Global Antihistamines Market, by Application, 2017 (US$ Mn)
2.4. Global Antihistamines Market, by Geography, 2017 (US$ Mn)

Chapter 3. Antihistamines: Market Dynamics and Outlook
3.1. Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Antihistamines Market, by Key Players, 2017

Chapter 4. Global Antihistamines Market, by Antihistamines Type, 2016-2026 (US$ Mn)
4.1. Overview
4.2. First Generation Antihistamines
4.2.1. Alimemazine
4.2.2. Chlorphenamine
4.2.3. Clemastine
4.2.4. Cyproheptadine
4.2.5. Hydroxyzine
4.2.6. Ketotifen
4.2.7. Promethazine
4.2.8. Others(Carbinoxamine, Dimenhydrinate, and others)
4.3. Second Generation Antihistamines
4.3.1. Acrivastine
4.3.2. Cetirizine
4.3.3. Desloratadine
4.3.4. Fexofenadine
4.3.5. Levocetirizine
4.3.6. Loratadine
4.4. Pipeline Analysis: Antihistamines Market
4.4.1. Phase III (Forecast till 2026)
4.4.2. Phase II (Tabular Representation)

Chapter 5. Global Antihistamines Market, by Application, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Allergic Rhinitis
5.3. Conjunctivitis
5.4. Urticaria
5.5. Atopic Dermatitis
5.6. Anaphylaxis
5.7. Others (Angioedema, Pruritus, and others)

Chapter 6. Global Antihistamines Market, by Geography, 2016-2026 (US$ Mn)

Chapter 7. Profiles

  • Bayer AG
  • Almirall S.A.
  • Johnson & Johnson
  • AstraZeneca plc
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Boehringer Ingelheim GmbH
  • Merck & Co., Inc.
  • Akorn, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Celgene Corporation
  • F. Hoffman-La Roche

For more information about this report visit

https://www.researchandmarkets.com/research/m9qg7m/global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.